Sanofi (SNYNF) Assets Average (2018 - 2026)
Sanofi (SNYNF) posted Assets Average of $148.7 billion for Q1 2026, down 0.62% sequentially from $149.7 billion in Q4 2025, and up 6.0% YoY from $140.3 billion in Q1 2025.
Sanofi (SNYNF) Assets Average (2018 - 2026) Analysis & Trends
Sanofi (SNYNF) has 3 years of Assets Average data on file, last reported at $148.7 billion in Q1 2026.
- Quarterly Assets Average rose 6.0% year-over-year to $148.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.7 billion (up 6.0% YoY) and the FY2025 annual result came in at $144.8 billion, up 3.88% from the prior year.
- Assets Average eased to $148.7 billion in Q1 2026 per SNYNF's latest filing, from $149.7 billion in the prior quarter.
- The five-year high for Assets Average was $149.7 billion in Q4 2025, with the low at $140.1 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 148.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 148.75 Bn |
| Dec 31, 2025 | 149.67 Bn |
| Sep 30, 2025 | 146.59 Bn |
| Jun 30, 2025 | 140.09 Bn |
| Mar 31, 2025 | 140.32 Bn |
| Dec 31, 2018 | 64.51 Bn |
| Sep 30, 2018 | 68.22 Bn |
| Jun 30, 2018 | 135.89 Bn |
| Mar 31, 2018 | 127.35 Bn |